Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-B7-1 Antibody (4I630) is a Mouse antibody targeting B7-1. Anti-B7-1 Antibody (4I630) can be used in ELISA,FCM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μL | $199 | 7-10 days |
Description | Anti-B7-1 Antibody (4I630) is a Mouse antibody targeting B7-1. Anti-B7-1 Antibody (4I630) can be used in ELISA,FCM. |
Alias | CD80 molecule |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 4I630 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of Human B7-1(CD80) expression on Daudi cells. Cells were stained with purified anti-Human B7-1(CD80), then a FITC-conjugated second step antibody. The histogram were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
Application | ELISA,FCM |
Recommended Dose | ELISA: 1:1000-1:2000; FCM: 1:25-1:100 |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD80 / B7-1 (rh CD80 / B7-1; TMPY-01063; Met 1-Asn 242; NP_005182.1). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
Conjucates | Unconjugated |
Others Formats | Biotin/FITC/PE |
Antibody Types Available | 4 |
Immunogen | Recombinant Human CD80 / B7-1 Protein (TMPY-01063) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.